Váš Lekár - polyclinic and pharmacies

Invest in a modern network of polyclinic, pharmacies, and outpatient clinics operated by Váš Lekár.

We are extending the investment campaign for the Váš Lekár group under more attractive terms for all investors in the special purpose company CB PHARMACY—both those who have already participated in the current round and new investors. 

The target company has already received EUR 1 million and the extension seeks to raise the remaining capital to reach the full target. 

At the same time, the business plan was updated and, given its slower fulfilment, we, after discussion with founder Pavol Marcinko, also reflected the change by adjusting the company’s valuation. Upon reaching the target amount of EUR 2.75 million, Crowdberry investors will therefore obtain a 33 % stake instead of the original 25 %. If the business plan targets are exceeded, the founder may reclaim part of the difference between the shareholding percentages. More details can be found in the Term Sheet. 

Investment together with existing and new investors will give you up to a 33 % stake in the holding company. Váš Lekár is an established provider of comprehensive healthcare, comprising the flagship polyclinic in Eurovea with 24 outpatient practices, a network of 6 regional outpatient clinics and 8 pharmacies, with expected revenues of roughly EUR 29 million by 2028. Through multiple services and business segments within healthcare, the group naturally diversifies your investment. 

Co‑own an established healthcare holding with an expected capital return of 2.5‑ to 4‑times the investment. Capital is directed towards opening and acquiring profitable pharmacies and operating the polyclinic. Within the investment campaign the first EUR 1,000,000 has been released. 

Every investor who invests at least EUR 5,000 can obtain a Service Package M at the Polyclinic. All investors, regardless of investment amount, may take advantage of discounted membership and pharmacy discounts across the Váš Lekár network.

Full conditions are in the Documents section. 

Key information about the investment 

• Form of investment: equity stake in the holding company 
• Equity available: investors can jointly acquire up to 33 % of the holding 
• Expected return: 25 % per year 
• Liquidity preference: payment of 1.5× the investment to new investors before the other co‑owners as a preferred return, plus further participation in profits to accelerate the target yield 
• Use of proceeds: acquisition of profitable pharmacies (according to the expansion plan), opening new pharmacies and financing the ramp‑up of the Eurovea polyclinic 

Sources of returns for investors 

• Exit / sale of individual companies, the entire holding, or investors’ stake upon entry of a new strategic investor 
• Payment of dividends after the group achieves profitability, as defined in the investment documentation and conditions 
• Buy‑back of investors’ stake by the holding with a 25 % annual return 

• Priority payout to investors: new investors (this round) are entitled to a payout of 1.5× their original investment ahead of the other co‑owners. 
• After satisfying new investors, existing investors are paid with a 1.3× preference on their investment and the founder with 1× his substantial seed investment. 
• Participation in additional profits: after all liquidity preferences are paid, investors are entitled to 15 % of further profits until the basic ratio is reached. 
• Profit split after achieving a 25 % annual return: if total paid returns equal a 25 % p.a. yield, all additional profits are shared evenly between this‑round investors and the other shareholders at 50/50. 

*Investing carries the risk of partial or complete loss of capital. The investment opportunity in the target company is facilitated by Crowdberry Investment Platform j.s.a.